| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2019 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Vice President, Finance | Sell | 967 | $42.91 | $41,493.97 | -8.6% | |
| Jun 4, 2019 | PCRX Pacira Biosciences, Inc. | McLoughlin Dennis64 | Chief Commercial Officer | Sell | 1,099 | $42.91 | $47,158.09 | -7.4% | |
| Jun 4, 2019 | PCRX Pacira Biosciences, Inc. | Laranjeira Charles Anthony61 | SVP, Technical Operations | Sell | 430 | $42.91 | $18,451.30 | -7.4% | |
| Jun 4, 2019 | LNTH Lantheus Holdings, Inc. | Schaffer Derace L | Director | Sell | 20,000 | $23.82 | $476,383.98 | -17.8% | |
| Jun 4, 2019 | DVAX Dynavax Technologies Corp | Coffman Robert | Senior Vice President | Sell | 32,218 | $4.58 | $147,687.31 | -29.3% | |
| Jun 3, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Barer Sol J | Director | Buy | 111,000 | $8.98 | $997,013.10 | +2,246% | |
| Jun 3, 2019 | PCRX Pacira Biosciences, Inc. | Scranton Richard | Chief Scientific Officer | Sell | 15,510 | $43.21 | $670,187.10 | -43.6% | |
| Jun 3, 2019 | HROW Harrow, Inc. | Kammer Robert J | Director | Sell | 10,000 | $5.78 | $57,800.00 | -1.2% | |
| Jun 3, 2019 | ZTS Zoetis Inc. | Chen Heidi C.47 | Executive Vice President | Sell | 2,500 | $104.23 | $260,575.00 | -17.9% | |
| Jun 3, 2019 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 3,435 | $85.51 | $293,718.61 | -2.4% | |
| Jun 3, 2019 | LLY Eli Lilly & Co | Harrington Michael J | Senior VP And General Counsel | Sell | 16,000 | $116.72 | $1,867,520.00 | -12.7% | |
| Jun 3, 2019 | COLL Collegium Pharmaceutical, Inc | Ciaffoni Joseph | President And CEO | Sell | 13,287 | $11.56 | $153,586.76 | -3.5% | |
| May 31, 2019 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 19,297 | $85.02 | $1,640,580.77 | -12.0% | |
| May 31, 2019 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 27,229 | $17.92 | $488,058.04 | -46.6% | |
| May 29, 2019 | AMRN Amarin Corp Plc\uk | Stack David M67 | Director | Sell | 33,799 | $18.45 | $623,534.09 | -100% | |
| May 29, 2019 | LNTH Lantheus Holdings, Inc. | Markison Brian A64 | Director | Sell | 5,000 | $24.29 | $121,453.50 | -8.0% | |
| May 28, 2019 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Buy | 168,630 | $14.00 | $2,360,820.00 | +10.5% | |
| May 28, 2019 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 1,376 | $43.39 | $59,702.44 | -5.6% | |
| May 24, 2019 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 17,486 | $80.03 | $1,399,434.31 | -11.0% | |
| May 24, 2019 | ANIP Ani Pharmaceuticals Inc | Nash David | Director | Buy | 1,445 | $68.76 | $99,358.20 | +38.1% | |
| May 23, 2019 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 110,000 | $24.88 | $2,736,428.00 | -7.1% | |
| May 23, 2019 | CPIX Cumberland Pharmaceuticals Inc | Jacobs Joey A | Director | Buy | 6,695 | $6.27 | $42,006.91 | +0.8% | |
| May 22, 2019 | LNTH Lantheus Holdings, Inc. | Markison Brian A64 | Director | Sell | 5,000 | $24.73 | $123,627.50 | -7.4% | |
| May 22, 2019 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 20,000 | $24.93 | $498,532.00 | -9.8% | |
| May 22, 2019 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 1,300 | $80.03 | $104,037.05 | -0.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.